New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2013
16:18 EDTTRGTTargacept sees FY13 revenue approximately $2.4M, consensus $2.95M
Expects its operating expenses for the year ending December 31 to be in the range of $48M-$54M and its cash, cash equivalents and investments balance at December 31 to be at least $135M. In addition, Targacept continues to expect that its current cash resources will be sufficient to meet its operating requirements at least through the end of 2015. This financial guidance includes both cash and non-cash revenue and expense items.
News For TRGT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 14, 2015
08:41 EDTTRGTTargacept says Catalyst CEO Nassim Usman to become CEO of combined company
Catalystís CEO Nassim Usman, Ph.D., will become the President and CEO of the combined company and the other Catalyst executive officers, Ed Madison, Ph.D., CSO and Fletcher Payne, CFO will assume their respective positions in the combined company. The seven-member board of directors of the combined company will be comprised of current Catalyst directors Harold E. Selick, Ph.D., Jeff Himawan, Ph.D., and Augustine Lawlor, as well as Dr. Usman, and current Targacept directors John P. Richard, Errol B. DeSouza, Ph.D. and Dr. Stephen A. Hill. Dr. Selick will serve as the new chairman of the board.
08:39 EDTTRGTTargacept, Catalyst Biosciences amend definitive merger agreement
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use